Symrise sales
This article was originally published in The Rose Sheet
Executive Summary
Scent and Care division revenues increased 6.5% on a local-currency basis to $1.03 bil. in 2007, the fragrance and flavor company announces March 5. The performance of the business was boosted by 10.6% growth in cosmetics and 8.5% local currency growth rate in fine fragrances based on "winning some major prestigious new fragrances in 2007," firm says. Symrise achieved net sales growth of 6.7% to $1.96 bil. in fiscal 2007 based on its concentration on fast-growing regions and business segments, German firm notes. Symrise is poised to maintain 5%-6% sales growth per year in 2008 and 2009, the company maintains...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.